RxDoctor Payments Data

Dieter Wefuan, MD

Internal Medicine · Kenansville, NCNPI 1073834917

Payments from drug & device makers

$306in general payments, 2019–2025

Across 11 payments — averaging $27.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$159
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$51
  • Amgen$35
  • Boehringer Ingelheim$22
  • Vanda Pharmaceuticals Inc.$14
  • MDD US Operations, LLC$14
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$306100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$306 in reported general payments places this provider in the 55th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$104,644
Medicare patients
215
Services billed
786

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$48,292
FarxigaDapagliflozin Propanediol11$9,420
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,359
Diltiazem 24hr Er (Cd)Diltiazem Hcl18$533
Torsemide16$237
Carvedilol32$226
Nifedipine ErNifedipine13$219
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen20$193
Atorvastatin Calcium27$163
Pantoprazole Sodium18$126
Losartan Potassium16$115
Cefdinir13$109
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$104
Furosemide16$80
Cephalexin12$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$11$9,42011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Kenansville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →